Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancer

Revolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company.

The approval is seen as a breakthrough in targeting the historically difficult RAS pathway, which has been a focus for many biotech firms seeking new cancer therapies.

Verastem Oncology executives discussed the development on a Fierce Biotech podcast, highlighting how the approval could open opportunities for other RAS-targeting drugs and shape future research.